These tests in oncology, cardiovascular, heritable eye diseases and rare genetic disorders shall be integrated into clinical practice by Apollo's subsidiary, Sapien Biosciences in partnership with Strand Life Sciences, it said in a statement on Thursday.

The statement further added, "These tests will help doctors diagnose disease more precisely, identify the optimal treatment and monitor disease and treatment course for better outcomes".

The latest genomic testing deals mainly with analysis of patient genomes, genes and sequences of DNA/RNA.

It would help to create better prognostic tools for improved disease screening and prevention strategies.

Latest News from State News Desk